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Background: New lymphatic vessels are associated with tissue injury and repair. Recent studies
have shown increased lymphatic follicles formation in the lungs of COPD patients. We hypoth-
esized that lymphatic vascular remodeling could be part of COPD pathogenesis.
Aim: To investigate the lymphangiogenetic process in COPD we measured the lymphatic micro-
vessel density (LMVD), the lymphatic invasion (L.I), and their correlation with clinical and labo-
ratory parameters.
Methods: Lung tissue from 20 COPD patients and 20 non-COPD smokers was immunohisto-
chemically stained for D2-40 (lymphatic endothelial cell marker), and LYVE-1 (lymphatic endo-
thelial hyaluronan receptor 1). Both groups had similar age and smoking history.
Results: D2-40 and LYVE-1 were expressed in all specimens. Lymphatic invasion was presented
only in COPD specimens. Lymphatic microvessel density (LMVD) as revealed by D2-40 and LYVE-
1 markers was statistically significantly higher in COPD patients when compared with non-COPD
smokers. Both markers (D2-40, LYVE-1) were correlated with FEV1 (% pred) (R2 Z 0.415,
R2 Z 0.605, respectively).
Conclusions: We report for the first time high lymphatic microvessel density and lymphatic
invasion in COPD patients, related to the degree of airway obstruction. Our findings could
provide novel insights in the pathogenesis of the disease.
ª 2011 Elsevier Ltd. All rights reserved.10 392433; fax: þ30 2810542650.
c.gr (E.G. Tzortzaki).
to this article.
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Table 1 Anthropometric and spirometric characteristics
of non-COPD and COPD subjects.Non COPD
median (IR)
COPD
median (IR)
p value
No of subjects 20 20
Age (years) 61 (16) 67 (9) 0.09
Sex (M/F) 18/2 19/1
Smoking
(packs/year)
50 (23) 65 (49) 0.17
FEV1 (%pred) 93 (29) 53 (22) <0.001a
FVC (%pred) 93 (22) 68 (24) <0.001a
FEV1/FVC 79 (10) 65 (7) <0.001a
a Statistically significant p value.Chronic obstructive pulmonary disease (COPD) is a major
public health and economical problem worldwide.1 It
affects about 10% of the general population but its preva-
lence among smokers may reach as much as 50%.1,2
Smoking, occupational exposures, environmental pollution
as well as certain genetic variations are some of the risk
factors for the disease.1e3 COPD is associated with
epithelial mucous metaplasia, inflammation, parenchymal
destruction and extensive lung remodeling in a way that is
difficult to maintain normal lung function.1,2,4
In a recent study Hogg et al2 demonstrated that the
disease progression correlates with the accumulation of
mucous exudates within the lumen and infiltration of the
walls by inflammatory cells that form lymphoid follicles.
These changes participate in the process of “remodeling”
that increases the thickness of the airways’ walls. The
lymphoid structures are generally the driver point of
chronic inflammation.2 Inflammatory cells and various
molecules (e.g. IL-1b, TNF-a, VEGF-C) have been recog-
nized to play important roles in lymphangiogenesis
(formation of lymphatic vessels) in experimental models5
and human diseases.6e11 In addition, soluble molecules,
such as hyaluronic acid, involved in lung injury and repair
can also induce lymphangiogenesis.12e14
Recently, El-Chemaly et al6 in order to test the
hypothesis whether lymphangiogenesis is part of the
“remodeling” in idiopathic pulmonary fibrosis (IPF)
demonstrated that the alveolar microenvironment in IPF
contains soluble factors (e.g. hyaluronic acid) and cells
(e.g. CD11b þ macrophages) that enhance lymphangio-
genesis. Although inflammatory cells, such as macrophages,
and lung mediators such as hyaluronic acid are common
features in COPD,2,4,5,8,9 no study thus far, investigated
lymphangiogenesis in COPD.
At present, the identification of lymphatic vessels in
normal tissue and in vascular malformations has been
considerably improved by the newly discovered lymphatic
endothelial markers, D2-40 and LYVE-1.13,14 We have
chosen the LYVE-1 (lymphatic vessel endothelial hyaluronan
receptor 1) and the D2-40 (a marker of lymphatic endo-
thelial cells) in order to evaluate the lymphatic microvessel
density (LMVD) and the presence of lymphatic invasion (L.I)
in COPD. LYVE-1 binds to hyaluronan on the luminal surface
of lymphatic vessels, while D2-40 specifically reacts with
lymphatic vessels, allowing identification of lymphatic
vessel invasion. Our findings demonstrated an intense
lymphangiogenetic process in COPD, significantly corre-
lated with the degree of airway obstruction.Methods
We have studied 40 smokers who underwent open lung
surgery for the excision of solitary pulmonary nodule.
Twenty subjects were diagnosed with COPD and 20 were
smokers without COPD. Table 1 presents the anthropo-
metric and spirometric data of the patients studied. The
surgical specimens were collected from the subpleural
parenchyma at least 5 cm away from the solitary nodule,from an uninvolved segment. Formalin-fixed paraffin-
embedded blocks of lung tissue were selected from each
case on the basis of containing viable COPD tissue and
surrounding normal lung parenchyma. The COPD viable
tissue was comprised of either enlarged air spaces
(emphysema) or infiltration by mononuclear inflammatory
cells, with scattered lumen occlusion by mucus plugging,
thickened walls by inflammation and fibrosis and promi-
nence of smooth muscles (chronic bronchitis). Areas with
necrosis were avoided and wedges were removed in case of
over-staining. The former pathology was absent from
normal controls. None of the specimens contained
neoplastic tissue.
Medical records (sex, age, spirometry values, and
disease stage) were thoroughly reviewed. Diagnosis and
staging of COPD patients were based upon GOLD classifi-
cation (Global Initiative for Chronic Obstructive Lung
Disease).2 All the procedures followed were in accordance
with international recommendations concerning human
research and ethical standards and were approved by the
Ethics Committee of the University Hospital of Heraklion,
Crete, Greece. Informed consent was obtained from all
patients participating in the study.
LYVE-1 protocol
Immunostaining of the formalin-fixed, paraffin embedded
tissue sections was performed (EnVision System, DAKO).
Consecutive 4 mm thick sections were sliced from each
tissue block and used for the immunohistochemical study.
Briefly, sections were deparaffinized and dehydrated to
distilled water. Microwave treatment was performed twice
in citrate buffer (pHZ 6), at 300 W, for 15 min. Endogenous
peroxidase was blocked by incubation in 3% hydrogen
peroxide in absolute methanol for 7 min in room tempera-
ture. Then, the slides were washed with distilled water,
and Tris Buffer Saline (TBS) (DAKO). The LYVE-1 (Lymphatic
Vessel Endothelial Receptor 1, R&D Systems), primary
antibody was used, with an incubation time of 60 min at
room temperature. The optimal dilution (1/50) was defined
on the basis of a titration experiment. Samples were
washed for 5 min. The incubation of the secondary mono-
clonal antibody against LYVE-1 followed, for 15 min. Slides
were washed with TBS for 5 min, incubated with peroxidase
streptavidin for 15 min, and then washed again for 5 min.
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was applied, followed by counterstaining with hematoxylin
10% (2e5 min), dehydration, mounting and coversliping.
D2-40 protocol
Formalin-fixed, paraffin embedded lung tissue sections of
4 mm were used. The automated slide processing system
BenchMark XT IHC/ISH Staining Module (Ventana Medical
Systems, Inc., Tucson, Arizona) was used for the optimiza-
tion and performance evaluation of the D2-40 lymphatic
marker (BioCare Medical). A protocol was established so
that the entire assay procedure consisting of baking,
deparaffinization, pretreatment, cell conditioning, titra-
tion, stringency wash, amplification, signal detection,
counterstaining and post counterstaining was completed as
a one-step fully automated assay (XT iVIEW DAB v3 proce-
dure). Specifically, the slide processing system automati-
cally performed the process starting with tissue
deparaffinization followed by three cycles of cell condi-
tioning (short-8 min conditioning, mild-30 min conditioning,
and standard-60 min conditioning). Titration took place by
placing the primary antibody D2-40 (an epitope of podo-
planin; a marker of lymphatic endothelial cells) (BioCare
Medical, 1/50 dilution) and then incubation for 32 min.
Antibody amplification in several stages followed, and
finally, counterstaining with hematoxylin 10% (4 min),
application of bluing reagent, incubation for 4 min and
coversliping were performed.
Assessment of D2-40 and LYVE-1 expression
Two experienced pathologists examined the slides without
any knowledge of the clinicopathological data. Examination
was simultaneously performed by means of a double
headed light microscope. Both pathologists had to reach
a consensus on what constituted a single vessel prior to its
inclusion in the count. The inter-observer coefficient of
variation was less than 10%.
Briefly, D2-40 and LYVE-1 expression was scored as the
percentage of stained cells in ten representative high
power fields (at least 1000 cells). The criteria for posi-
tiveness were a cytoplasmatic staining irrespective of
intensity of D2-40 and LYVE-1.15e18 Positively stained
inflammatory cells were excluded from counting.
The D2-40 and LYVE-1 expression assessment was carried
out using a semiquantitative scale with the following
correspondence: (þ): low expression, (þþ): medium
expression, (þþþ): high expression, according to Volm
et al.17
Regarding D2-40 and LYVE-1 quantitative expression, the
three most vascular areas (hot spots) within a section were
selected for evaluation on a light microscope (Olympus BX-
51) in low magnification (100). The labeled vessels with
the anti-D2-40 and anti-LYVE-1 monoclonal Abs were
counted under a light microscope at 400 magnification.
The average counts exhibited the lymphatic microvessel
density (LMVD). The median of all densities was measured
for each antibody and was further used as a cut-off value
for high and low expression. The score was defined as
follows: low expression D2-40; LMVD < 81, low expressionLYVE-1; LMVD < 594, high expression D2-40; LMVD  81,
high expression LYVE-1; LMVD  594. Areas of necrosis were
excluded.19e22 Lymphatic vessel invasion was additionally
investigated by the presence of emboli within cells stained
with D2-40 and LYVE-1.Statistical analysis
The normality was evaluated using ShapiroeWilk criterion.
For the not normally distributed variables, non parametric
methods analysis was used. Continuous variables were
expressed as median, while categorical variables as abso-
lute and relative frequencies. ManneWhitney test and
KruskaleWallis test were applied for the analysis of group
differences within continuous variables. Correlation
between continuous variables was assessed with Spear-
man’s correlation coefficient. A two sided p-value of less
than 0.05 was considered statistically significant. The
Statistical Package for Social Sciences (SPSS) program,
version 16.0 (Chicago, Illinois, USA) was used for statistical
analysis.Results
We retrospectively evaluated 40 subjects; 20 COPD patients
and 20 non-COPD smokers. All subjects were matched for
age and had a similar smoking exposure (Table 1). The
majority of COPD patients (14/20) were in stages 1 and 2
(GOLD).D2-40 expression
All COPD patients showed increased LMVDD2-40 (81)
expression as compared with non-COPD smokers [(LMVDD2-
40 (<81)]. Lymphatic invasion (L.I.) was exhibited only in
COPD patients. Fig. 1ai shows a typical COPD smoker with
emphysematous changes and abnormal enlargement of the
air spaces presenting high LMVDD2-40 (81). Fig. 1aii shows
a COPD smoker with typical findings of bronchitis with small
bronchioles infiltrated by mononuclear inflammatory cells
and scattered lumen occlusion by mucus plugging, pre-
senting high LMVDD2-40 (81) expression. Fig. 1b shows
a representative tissue specimens of a non-COPD smoker
exhibiting low LMVDD2-40 (<81) expression.
LMVDD2-40 expression was statistically significantly
increased in patients with COPD as compared with non-
COPD smokers (ManneWhitney test, U < 0.001,
p < 0.001) (Fig. 2). In detail, in the D2-40 marker, 35% of
COPD patients exhibited increased expression (þþþ), 40%
medium (þþ) and 25% low (þ). In non-COPD smokers the
D2-40 expression was high (þþþ) only in 5% of the samples,
medium (þþ) in 70% and low (þ) in 25% of the cases.
Furthermore, LMVDD2-40 was significantly correlated with
FEV1 (%pred) (Correlationcoefficient SpearmanZ rSZ0.7,
p< 0.001) as it is shown in Fig. 3. Interestingly, COPD patients
exhibiting increased LMVDD2-40  81 expression had lower
FEV1 (% pred) values (median 53), while subjects with low
LMVDD2-40 < 81 expression had higher FEV1 (% pred) values
(median 93), (Fig. 3).
Figure 1 ai A representative tissue sample of a COPD patient showing abnormal enlargement of the air spaces (emphysema) and
high LMVDD2-40 (81) expression. The D2-40 marker stained selectively the walls of the lymphatic vessels (magnification  40). aii A
tissue sample of a COPD patient exhibiting typical findings of bronchitis with small bronchioles infiltrated by mononuclear
inflammatory cells and scattered lumen occlusion by mucus plugging and high LMVDD2-40 (81) expression (magnification  100).
b A tissue sample of a typical smoker without COPD with low LMVDD2-40 (<81) expression (magnification 100).
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All COPD patients showed increased LMVDLYVE-1 (594)
expression as compared with non-COPD smokers. In detail,
60% of COPD patients exhibited high (þþþ), 35% medium
(þþ) and 5% low (þ) LYVE-1 expression, while 35% of non-
COPD smokers exhibited high (þþþ), 40% medium (þþ)
and 25% low (þ) LYVE-1 expression.Figure 2 Median and standard deviation of LMVDD2-40 in
smokers with and without COPD (p < 0.001).
Figure 3 Scatter-plot between Lymphatic Microvascular
density D2-40 and FEV1 (% pred) in COPD and non-COPD
smokers (r Z 0.7, p < 0.001).
Figure 5 Median values of LMVDLYVE-1 in smokers with and
without COPD (p < 0.001).
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tous changes and abnormal enlargement of the air spaces
presenting high LMVDLYVE-1 (594) expression, while Fig. 4b
shows a representative tissue specimens of a non-COPD
smoker with low LMVDLYVE-1 (<594) expression. LMVDLYVE-1
was statistically significantly increased in patients with
COPD versus non-COPD smokers (ManneWhitney test,
U < 0.001, p < 0.001) (Fig. 5).
Regarding spirometric data, LMVDLYVE-1 was significantly
correlated with FEV1 (% pred) values (Correlation coeffi-
cient Spearman Z rS Z 0.8, p < 0.001) (Fig. 6). Inter-
estingly, COPD patients presenting increased LMVDLYVE-
1  594 expression had lower FEV1 (% pred) values (median
53) as compared to subjects with low LMVDLYVE-1<594
expression and higher FEV1 (% pred) values (median 93),
(Fig. 6).
Discussion
To the best of our knowledge, this is the first study to report
high lymphatic microvessel density (LMVD) and lymphatic
invasion (L.I.) in COPD patients. Additionally, both LMVD
and LI were related to the degree of airway obstruction.Figure 4 a A typical tissue sample of a COPD smoker exhib-
iting emphysematous changes, abnormal enlargement of the
air spaces, and high LMVDLYVE-1 (594) expression (magnifica-
tion 100). b A typical tissue sample of a non-COPD smoker
showing low LMVDLYVE-1 (<594) expression (x200).Lymphangiogenesis plays an important physiological role
in homeostasis, metabolism and immunity.22 Lymphatic
vessel formation has been implicated in a number of
pathological conditions including neoplasm metastasis,
edema, impaired wound healing, rheumatoid arthritis,
psoriasis, lung fibrosis and asthma. In addition, lymphoid
follicles (LF), known to participate in adaptive humoral and
T-cellemediated responses to antigens, are induced by
chronic inflammation or infection.22,23 Increased number of
LF was found in advanced COPD.2,3 However, the cellular
and molecular mechanisms that contribute to the forma-
tion of LF and lymphatic vessels in the lungs of COPD
subjects are not entirely understood.Figure 6 Scatter-plot between Lymphatic Microvascular
Density LYVE-1 and FEV1 (%pred) in COPD and non-COPD
smokers (r Z 0.8, p < 0.001).
692 G. Hardavella et al.Our results showed increased expression of LYVE-1 and
D2-40 monoclonal antibodies (which selectively recognise
the lymphatic endothelium), in COPD patients compared
with non-COPD smokers, and this was correlated with the
severity of the disease.
We believe that our data may possibly be interpreted by
two ways; firstly, could point out a novel link in the auto-
immunity component of COPD, and secondly, could reveal
an impaired wound healing process leading to the abnormal
lung tissue remodeling, or both.
The model that we propose could be the following:
Initially, cigarette smoke injures lung epithelial cells which
release “danger signals” that act as ligands for toll-like
receptors (TLRs) in the epithelium.24 This model has been
initially introduced with the discovery of the endogenous,
non-foreign “alarm signals”, including altered host DNA,
RNA, and proteins.25,26 Additionally, the by-products from
host inflammatory cells such as reactive oxygen species
may further promote tissue injury, and “auto-antigen”
production. This chain of events may cause dendritic cells
to mature and to migrate to local lymph organs, where, if
the conditions are favorable, T-cell activation may
result.24,26,27 Our findings exhibiting high microvessel
density in the lungs of COPD patients may indicate another
component of the regional adaptive immune response.
Thus, the network of the new lymphatic vessels in the lungs
of COPD patients might be simply the “short cut” which
facilitates the “journey” of “danger signals” toward
regional lymph nodes; in order to obtain a quicker and
constant immune response. It has been proposed that COPD
has an autoimmune component and that LF participate in
this process.4,28,29 Up to now, there is scant information
regarding the presence of lymphatics and lymphangio-
genesis in the pathogenesis of chronic lung diseases, such as
COPD.9 Baluk et al5 investigated the role of lymphangio-
genesis in a mouse model of chronic airway inflammation.
They found extensive growth of lymphatic vessels in
infected airways. Inhibition of lymphatic growth exacer-
bated mucosal edema and reduced the hypertrophy of
draining lymph nodes, demonstrating that when lym-
phangiogenesis is impaired, airway inflammation may lead
to bronchial lymphedema and airflow obstruction.5
An alternative explanation for our data might be that
lymphangiogenesis in COPD represent another component
of the abnormal remodeling process. In this study,
lymphatic microvessel density (LMVD) was increased as the
disease progressed while lymphatic invasion (L.I) was
present only in COPD specimens. Normal lung parenchyma
is generally devoid of lymphatics, except for lymphatic
vessels within bronchovascular tissue. Studies of lymphatics
in healthy human lung are rare. Pusztaszeri et al30 found
that D2-40 reactivity followed the bronchovascular distri-
bution, and was nonexistent or rare in the alveoli. Yama-
shita et al31 showed that normal lymphatic vessels are in
close proximity with the large bronchovascular trees and
not present in the alveolar spaces. More recently, Kam-
bouchner et al.32 showed that about 3.6%e19% of alveolar
spaces had an associated D2-40-reactive lymphatic vessel,
in areas of healthy lung in the vicinity of excised tumors.
Another interesting point of this study was that LMVDD2-
40 and LMVDLYVE-1 markers were negatively correlated with
FEV1 (% pred) as shown in Figs. 3 and 5, respectively. COPDpatients who presented increased lymphangiogenesis had
lower FEV1 (% pred) values as compared to smokers without
COPD and low lymphangiogenesis. Likewise, Hoshino et al.7
found more vessels and a larger vascular area in patients
with atopic, mild to moderate asthma when compared with
control subjects. They also reported an inverse correlation
between FEV1 (% pred) and/or airway responsiveness and
the percentage of vessel area. In agreement with our
results, Hashimoto et al.8 reported increased vascularity in
the medium and small airways of patients with asthma
which was correlated with disease severity in mild and
moderate asthma.8 The above findings strongly suggest that
airway vascularity (angiogenesis and lymphangiogenesis) is
enhanced and correlates with disease severity providing
evidence that the endothelium is proliferating contributing
to the airway remodeling.33
In conclusion, our results demonstrated significantly
increased expression of the lymphatic endothelial markers
D2-40 and LYVE-1 in COPD patients when compared with
non-COPD smokers, and this was related to the severity of
the disease. Although lymphatic vascular remodeling has
not been studied up to now in COPD, it appears that lung
lymphangiogenesis constitute another link in the adaptive
immune response or/and airway remodeling as the disease
progresses. Better understanding of the above pathways
may put forward novel therapeutic targets in COPD.Author contributions
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